- Home
- PALI vs CERO Comparison
PALI vs CERO Comparison
Compare PALI & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- CERO
- Stock Information
- Founded
- PALI 1996
- CERO 2017
- Country
- PALI United States
- CERO United States
- Employees
- PALI N/A
- CERO N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- CERO
- Sector
- PALI Health Care
- CERO
- Exchange
- PALI Nasdaq
- CERO Nasdaq
- Market Cap
- PALI 3.7M
- CERO 3.5M
- IPO Year
- PALI N/A
- CERO N/A
- Fundamental
- Price
- PALI $0.75
- CERO $8.90
- Analyst Decision
- PALI Strong Buy
- CERO Strong Buy
- Analyst Count
- PALI 2
- CERO 2
- Target Price
- PALI $12.00
- CERO $45.00
- AVG Volume (30 Days)
- PALI 298.7K
- CERO 3.3M
- Earning Date
- PALI 08-11-2025
- CERO 08-13-2025
- Dividend Yield
- PALI N/A
- CERO N/A
- EPS Growth
- PALI N/A
- CERO N/A
- EPS
- PALI N/A
- CERO N/A
- Revenue
- PALI N/A
- CERO N/A
- Revenue This Year
- PALI N/A
- CERO N/A
- Revenue Next Year
- PALI N/A
- CERO N/A
- P/E Ratio
- PALI N/A
- CERO N/A
- Revenue Growth
- PALI N/A
- CERO N/A
- 52 Week Low
- PALI $0.60
- CERO $6.71
- 52 Week High
- PALI $4.89
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- PALI 55.44
- CERO 46.23
- Support Level
- PALI $0.70
- CERO $8.50
- Resistance Level
- PALI $0.76
- CERO $9.73
- Average True Range (ATR)
- PALI 0.04
- CERO 1.20
- MACD
- PALI 0.01
- CERO -0.01
- Stochastic Oscillator
- PALI 77.65
- CERO 14.54
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.